-+ 0.00%
-+ 0.00%
-+ 0.00%

Alvotech says FDA accepts AVT16 biosimilar application for review

PUBT·06/08/2026 08:00:17
Listen to the news
Alvotech says FDA accepts AVT16 biosimilar application for review
  • Alvotech’s BLA for AVT16, a proposed interchangeable biosimilar to Takeda’s Entyvio, was accepted for FDA review.
  • Teva will commercialize AVT16 under the partners’ agreement. Alvotech will handle development, manufacturing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606080400PRIMZONEFULLFEED1001186167) on June 08, 2026, and is solely responsible for the information contained therein.